Literature DB >> 14736820

Bayesian analysis and risk assessment in genetic counseling and testing.

Shuji Ogino1, Robert B Wilson.   

Abstract

Risk assessment is an essential component of genetic counseling and testing, and Bayesian analysis plays a central role in genetic risk assessment. Bayesian analysis allows calculation of the probability of a particular hypothesis, either disease or carrier status, based on family information and/or genetic test results. Genetic risk should be assessed as accurately as possible for family decision making. Additional information, from the pedigree and/or from genetic testing, can often dramatically improve the accuracy of genetic risk assessment. We illustrate herein the application of Bayes' theorem and describe important basic principles in genetic risk assessment.

Mesh:

Year:  2004        PMID: 14736820      PMCID: PMC1867463          DOI: 10.1016/S1525-1578(10)60484-9

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  11 in total

1.  A genetic risk calculation surprise.

Authors:  P Flodman; S E Hodge
Journal:  Am J Med Genet       Date:  2001-04-22

Review 2.  Pitfalls in the interpretation of molecular diagnostic tests.

Authors:  B R Korf
Journal:  J Clin Lab Anal       Date:  1996       Impact factor: 2.352

3.  Risk tables for genetic counselling in some common congenital malformations.

Authors:  C Bonaiti-Pellié; C Smith
Journal:  J Med Genet       Date:  1974-12       Impact factor: 6.318

4.  Recurrence risks for multifactorial inheritance.

Authors:  C Smith
Journal:  Am J Hum Genet       Date:  1971-11       Impact factor: 11.025

Review 5.  Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening.

Authors:  Joseph L Bobadilla; Milan Macek; Jason P Fine; Philip M Farrell
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

6.  Recurrence risk for germinal mosaics revisited.

Authors:  M A van der Meulen; M J van der Meulen; G J te Meerman
Journal:  J Med Genet       Date:  1995-02       Impact factor: 6.318

Review 7.  Genetic testing and risk assessment for spinal muscular atrophy (SMA).

Authors:  Shuji Ogino; Robert B Wilson
Journal:  Hum Genet       Date:  2002-10-03       Impact factor: 4.132

8.  Computer programme to estimate recurrence risks for multifactorial familial disease.

Authors:  C Smith
Journal:  Br Med J       Date:  1972-02-19

9.  Laboratory standards and guidelines for population-based cystic fibrosis carrier screening.

Authors:  W W Grody; G R Cutting; K W Klinger; C S Richards; M S Watson; R J Desnick
Journal:  Genet Med       Date:  2001 Mar-Apr       Impact factor: 8.822

10.  Standards and guidelines for CFTR mutation testing.

Authors:  Carolyn Sue Richards; Linda A Bradley; Jean Amos; Bernice Allitto; Wayne W Grody; Anne Maddalena; Matthew J McGinnis; Thomas W Prior; Bradley W Popovich; Michael S Watson; Glenn E Palomaki
Journal:  Genet Med       Date:  2002 Sep-Oct       Impact factor: 8.822

View more
  6 in total

1.  Bayesian risk assessment for autosomal recessive diseases: fetal echogenic bowel with one or no detectable CFTR mutation.

Authors:  S Ogino; R B Wilson; W W Grody
Journal:  J Med Genet       Date:  2004-05       Impact factor: 6.318

2.  Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders--updated European recommendations.

Authors:  Els Dequeker; Manfred Stuhrmann; Michael A Morris; Teresa Casals; Carlo Castellani; Mireille Claustres; Harry Cuppens; Marie des Georges; Claude Ferec; Milan Macek; Pier-Franco Pignatti; Hans Scheffer; Marianne Schwartz; Michal Witt; Martin Schwarz; Emmanuelle Girodon
Journal:  Eur J Hum Genet       Date:  2008-08-06       Impact factor: 4.246

3.  Bayesian Assessment of Genetic Risk in Families with a Balanced Translocation.

Authors:  Douglas VanDerwerken
Journal:  J Genet Couns       Date:  2015-02-04       Impact factor: 2.537

4.  Bayesian risk assessment in genetic testing for autosomal dominant disorders with age-dependent penetrance.

Authors:  Shuji Ogino; Robert B Wilson; Bert Gold; Pamela Flodman
Journal:  J Genet Couns       Date:  2007-02-13       Impact factor: 2.537

5.  Cardiovascular genetics: technological advancements and applicability for dilated cardiomyopathy.

Authors:  G J M Kummeling; A F Baas; M Harakalova; J J van der Smagt; F W Asselbergs
Journal:  Neth Heart J       Date:  2015-07       Impact factor: 2.380

Review 6.  Understanding False Negative in Prenatal Testing.

Authors:  Mark I Evans; Ming Chen; David W Britt
Journal:  Diagnostics (Basel)       Date:  2021-05-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.